Black Diamond Therapeutics, Inc. financial data

Symbol
BDTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Main Street, 14 Th Floor, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Aset Therapeutics, Inc. (to 1/4/2018)
Latest financial report
10-Q - Q3 2024 - Nov 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 654 % -21.6%
Debt-to-equity 37.2 % +4.12%
Return On Equity -68.2 % +12.8%
Return On Assets -49.7 % +13.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 56.6M shares +9.59%
Common Stock, Shares, Outstanding 56.5M shares +9.46%
Entity Public Float 115M USD +106%
Common Stock, Value, Issued 7K USD 0%
Weighted Average Number of Shares Outstanding, Basic 56.5M shares +10.9%
Weighted Average Number of Shares Outstanding, Diluted 56.5M shares +10.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 54.3M USD -7.44%
General and Administrative Expense 27.1M USD -6.01%
Operating Income (Loss) -81.4M USD +6.97%
Nonoperating Income (Expense) 8.26M USD +47.7%
Net Income (Loss) Attributable to Parent -73.1M USD +13.1%
Earnings Per Share, Basic -1.33 USD/shares +37.6%
Earnings Per Share, Diluted -1.33 USD/shares +37.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23.4M USD -59.6%
Assets, Current 116M USD -21.4%
Property, Plant and Equipment, Net 1.47M USD -18.9%
Operating Lease, Right-of-Use Asset 19.8M USD -12.9%
Other Assets, Noncurrent 293K USD
Assets 138M USD -20%
Accounts Payable, Current 1.97M USD +184%
Employee-related Liabilities, Current 4.25M USD -6.35%
Accrued Liabilities, Current 18.8M USD +31%
Liabilities, Current 20.8M USD +38.1%
Operating Lease, Liability, Noncurrent 19.7M USD -14.5%
Liabilities 40.5M USD +6.32%
Accumulated Other Comprehensive Income (Loss), Net of Tax 107K USD
Retained Earnings (Accumulated Deficit) -471M USD -18.4%
Stockholders' Equity Attributable to Parent 97.4M USD -27.5%
Liabilities and Equity 138M USD -20%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.2M USD -5.83%
Net Cash Provided by (Used in) Financing Activities 4.13M USD +7998%
Net Cash Provided by (Used in) Investing Activities -13.7M USD -155%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 56.5M shares +9.46%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -30.8M USD -738%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 24.3M USD -58.8%
Deferred Tax Assets, Valuation Allowance 111M USD +26.6%
Deferred Tax Assets, Gross 117M USD +24%
Operating Lease, Liability 23M USD -11.7%
Depreciation 86K USD -29.5%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -72.6M USD +11.4%
Lessee, Operating Lease, Liability, to be Paid 27.2M USD -13.8%
Property, Plant and Equipment, Gross 2.53M USD -0.98%
Operating Lease, Liability, Current 3.33M USD +9.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.6M USD +2.73%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.48M USD +2.71%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.16M USD -23.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.72M USD +2.72%
Deferred Tax Assets, Operating Loss Carryforwards 69.2M USD +14.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.93M USD -16.9%
Operating Lease, Payments 1.08M USD +2.76%
Additional Paid in Capital 568M USD +6.71%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 5.93M USD -9.88%
Share-based Payment Arrangement, Expense 10.5M USD -4.07%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%